Newsfeeds - Spark Newswire

4 minute read

Dyne Therapeutics Presents Preclinical Data From Its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 At World Muscle Society 2022 Congress October 11-15

Today, 8:34 PM

- Poster Highlights In Vivo Data for DYNE-251, Now Being Evaluated in Phase 1/2 DELIVER Clinical Trial in Patients Amenable to Exon 51 Skipping - - First Presentation of In Vitro Data for FORCE™ Platform

DYN

3 minute read

Dyne Therapeutics Highlights DM1 and DMD Clinical Programs During ‘Spotlight on the Clinic’ Virtual Event

By Bill Haddad

Today, 8:34 PM

- Presentation and Discussion with Two Leading Neuromuscular Disease Experts - - Data from DYNE-101 ACHIEVE and DYNE-251 DELIVER Clinical Trials Anticipated in the Second Half of 2023 - - Refined Focus on

DYN

2 minute read

Dyne Therapeutics Announces First Patient Dosed In Phase 1/2 DELIVER Clinical Trial Of DYNE-251 For The Treatment Of Duchenne Muscular Dystrophy

By Bill Haddad

Today, 8:34 PM

Data from Global, Multiple Ascending Dose DELIVER Trial Anticipated in the Second Half of 2023 - - Dyne to Host “Spotlight on the Clinic” Virtual Event on September 12 - WALTHAM, Mass., Sept. 06, 2022

DYN

1 minute read

News

Dyne Therapeutics Announces “Breakthrough Article” Publication Of Duchenne Muscular Dystrophy Program Data In Nucleic Acids Research

By Benzinga Newsdesk

Today, 8:34 PM

- FORCE™ Platform Achieves Enhanced Exon Skipping and Prolonged Dystrophin Restoration in Duchenne in vivo mdx Model -

DYN

1 minute read

Chardan Initiates Coverage On These ‘Intriguing Small-Cap Stories”

By Vandana Singh

Today, 8:34 PM

Chardan Research initiated coverage on Avidity Biosciences Inc (NASDAQ:RNA) with a Buy rating and a price target of $29 and Dyne Therapeutics Inc (NASDAQ:DYN) with…

DYN

1 minute read

Avidity Biosciences Or Dyne Therapeutics – Read On Raymond James’ Rating Skew

By Vandana Singh

Today, 8:34 PM

Raymond James initiated coverage on Avidity Biosciences Inc (NASDAQ:RNA) with a Strong Buy rating and $29 price target (68% upside) and Dyne Therapeutics Inc (NASDAQ:DYN)…

DYN